Jones Hill Capital LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2102314) · Explore on the interactive board
Jones Hill Capital LP disclosed 29 US equity positions worth $470.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 13, 2026). Its largest position is BMRN at 17.4% of the reported book, followed by GILD, ARQT. The top ten holdings are 68.8% of the book, and the portfolio behaves like about 15 equal-weight positions. Versus the prior filing it opened 15 new positions, added to 5, reduced 9 and exited 12. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Jones Hill Capital LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 15 new, 5 added, 9 reduced, 12 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 17.4% | $81.9m | 1,431,590 | 13% | added |
| 2 | GILD GILEAD SCIENCES INC | Healthcare | 9.2% | $43.3m | 343,043 | – | new |
| 3 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 6.1% | $28.6m | 1,089,701 | – | new |
| 4 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 6.0% | $28.2m | 52,545 | – | new |
| 5 | BCAX BICARA THERAPEUTICS INC | Healthcare | 5.6% | $26.5m | 892,621 | -29% | reduced |
| 6 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 5.4% | $25.3m | 3,655,075 | 966% | added |
| 7 | TRVI TREVI THERAPEUTICS INC | Healthcare | 5.3% | $25.0m | 1,339,212 | 262% | added |
| 8 | PHVS PHARVARIS N V | Healthcare | 5.0% | $23.4m | 677,879 | 306% | added |
| 9 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.7% | $22.2m | 367,900 | – | new |
| 10 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 4.1% | $19.4m | 233,808 | -27% | reduced |
| 11 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 3.5% | $16.3m | 512,856 | – | new |
| 12 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 3.4% | $16.1m | 894,058 | -44% | reduced |
| 13 | INSM INSMED INC | Healthcare | 2.8% | $13.0m | 122,375 | – | new |
| 14 | NUVALENT INC | 2.6% | $12.2m | 98,442 | -67% | reduced | |
| 15 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 2.2% | $10.1m | 420,751 | -54% | reduced |
| 16 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 2.0% | $9.3m | 1,759,492 | – | new |
| 17 | IMUX IMMUNIC INC | 1.8% | $8.3m | 539,814 | – | new | |
| 18 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.7% | $8.1m | 747,313 | – | new |
| 19 | TNXP TONIX PHARMACEUTICALS HLDG C | 1.7% | $8.0m | 625,428 | 38% | added | |
| 20 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.6% | $7.4m | 340,000 | – | new |
| 21 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.5% | $7.2m | 574,166 | – | new |
| 22 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.4% | $6.7m | 659,213 | -45% | reduced |
| 23 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.3% | $6.1m | 653,572 | – | new |
| 24 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.2% | $5.6m | 57,100 | – | new |
| 25 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 1.2% | $5.5m | 11,123 | -90% | reduced |
| 26 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.5% | $2.5m | 49,850 | -92% | reduced |
| 27 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.5% | $2.2m | 40,567 | -60% | reduced |
| 28 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.4% | $1.8m | 161,486 | – | new |
| 29 | ACHV ACHIEVE LIFE SCIENCE INC | 0.0% | $174.7k | 26,760 | – | new |
What did Jones Hill Capital LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| PCVX VAXCYTE INC | 23.5% | $37.5m |
| 430 TERNS PHARMACEUTICALS INC | 17.2% | $27.5m |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 15.3% | $24.4m |
| ARGX ARGENX SE | 11.9% | $19.0m |
| FULC FULCRUM THERAPEUTICS INC | 8.5% | $13.6m |
| NUVB NUVATION BIO INC | 6.4% | $10.2m |
| ORKA ORUKA THERAPEUTICS INC | 4.3% | $6.9m |
| CTNM CONTINEUM THERAPEUTICS INC | 4.2% | $6.7m |
| MANE VERADERMICS INC | 4.0% | $6.4m |
| TRDA ENTRADA THERAPEUTICS INC | 3.0% | $4.7m |
| SLN SILENCE THERAPEUTICS PLC | 1.0% | $1.6m |
| AVBP ARRIVENT BIOPHARMA INC | 0.7% | $1.1m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 93.9% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Jones Hill Capital LP's portfolio?
Across every quarter Jones Hill Capital LP has filed, its median largest position is 16.4% of the book and its median top-ten weight is 71.0%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 29.0 positions are still open and their final length is unknown.